Building a Peptide Stack for Recovery and Performance

Peptide therapy has matured past the era of single-compound protocols. While individual peptides like BPC-157 or Thymosin Alpha-1 deliver meaningful results on their own, the real clinical breakthroughs happen when peptides are combined into purpose-built stacks — targeted combinations where each compound amplifies the other.

But stacking isn't mixing and matching at random. The wrong combination can blunt efficacy, introduce unnecessary side effects, or simply waste money. The right combination, built on mechanistic logic and clinical experience, produces results that neither peptide achieves alone.

"Stacking peptides is like building a recipe. Each ingredient serves a purpose. If you throw in everything, you get chaos. If you pair the right compounds at the right doses with the right timing, you get something greater than the sum of its parts."

— Dr. Adrian Kovac, Hatter Labs

Why Stack Peptides?

Most biological outcomes — tissue repair, sleep architecture, immune defense, fat metabolism — are not governed by a single pathway. They involve cascades of signaling molecules, receptor interactions, and feedback loops. A single peptide addresses one node in that network. A well-designed stack addresses multiple nodes simultaneously.

Consider tissue repair. BPC-157 accelerates angiogenesis (new blood vessel formation) and modulates growth factor expression. TB-500 promotes cellular migration and reduces inflammation at the injury site. Individually, each helps. Together, you get accelerated blood supply to the injury (BPC-157) combined with faster cellular repair at that now-well-supplied site (TB-500). The synergy is biological, not theoretical.

Dr. Kovac organizes his stacking philosophy around five clinical goals. Each stack below represents his most-prescribed combination for that goal, refined across years of practitioner feedback and patient outcomes.

Stack 1: Tissue Recovery — BPC-157 + TB-500

This is the foundational recovery stack. If you prescribe one peptide combination, make it this one.

The Rationale

BPC-157 (Body Protection Compound) is a gastric pentadecapeptide that promotes angiogenesis, modulates nitric oxide synthesis, and upregulates growth hormone receptors in injured tissue. TB-500 (Thymosin Beta-4) regulates actin, a cell-building protein critical for tissue repair, and has potent anti-inflammatory and anti-fibrotic effects.

Together, BPC-157 creates the vascular infrastructure for healing while TB-500 drives the cellular repair process. They address different but complementary phases of tissue recovery.

Dosing Protocol

• BPC-157: 250-500 mcg daily, subcutaneous injection near the injury site (or abdominally for systemic effect)
• TB-500: 2.5 mg twice weekly for the first 4 weeks (loading phase), then 2.5 mg once weekly (maintenance)
• Timing: BPC-157 in the morning; TB-500 on non-consecutive days (e.g., Monday/Thursday)

Expected Timeline

• Week 1-2: Reduced pain and inflammation at injury site
• Week 3-4: Noticeable improvement in range of motion and tissue integrity
• Week 5-8: Significant functional recovery; many soft tissue injuries resolve

Monitoring

Baseline CBC and CMP. Symptom tracking every 2 weeks. Imaging reassessment at 6-8 weeks for structural injuries.

"BPC-157 and TB-500 together is the closest thing we have to a universal tissue repair protocol. I've seen tendons, ligaments, and post-surgical patients respond to this combination in ways that surprise even skeptical orthopedic surgeons."

— Dr. Adrian Kovac, Hatter Labs

Stack 2: Sleep Optimization — DSIP + Epithalon

The Rationale

DSIP (Delta Sleep-Inducing Peptide) directly promotes delta wave sleep — the deepest, most restorative sleep phase responsible for growth hormone release, memory consolidation, and immune function. Epithalon (Epitalon) is a tetrapeptide that regulates the pineal gland's production of melatonin and has demonstrated telomere-protective effects.

DSIP addresses sleep architecture quality in the short term. Epithalon normalizes the circadian rhythm at its source — the pineal gland. Together, they rebuild both the depth and the timing of restorative sleep.

Dosing Protocol

• DSIP: 100-300 mcg subcutaneously, 30-60 minutes before bed
• Epithalon: 5-10 mg daily for 20 consecutive days, then off for 4-6 months (cycling is essential)
• Timing: DSIP nightly during the Epithalon cycle; DSIP can continue independently as needed after the Epithalon course

Expected Timeline

• Night 1-3: Many patients report deeper sleep and more vivid dreams from DSIP alone
• Week 1-2: Sleep onset latency improves; nighttime waking decreases
• Week 3-4: Circadian rhythm stabilization becomes apparent — consistent wake times, natural morning alertness
• Post-cycle: Sleep improvements from Epithalon persist for months after the 20-day course

Monitoring

Sleep tracking (wearable or sleep diary). Morning cortisol at baseline and 4 weeks. Subjective energy and recovery scores.

Stack 3: Body Composition — AOD-9604 + CJC-1295

The Rationale

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without the insulin resistance or other side effects of full-length HGH. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that amplifies the body's natural pulsatile GH release.

AOD-9604 directly targets fat metabolism. CJC-1295 elevates the growth hormone environment that supports both fat loss and lean tissue preservation. The combination shifts body composition from two angles — breaking down stored fat while promoting the hormonal milieu that favors muscle over adipose.

Dosing Protocol

• AOD-9604: 300 mcg daily, subcutaneous, on an empty stomach (morning or before bed)
• CJC-1295 (no DAC): 100 mcg subcutaneously before bed, 5 days on / 2 days off
• Cycle: 12-week cycle, 4 weeks off, reassess

Expected Timeline

• Week 1-3: Improved sleep quality (GH effect), subtle changes in body water distribution
• Week 4-6: Measurable reduction in visceral fat; patients report clothes fitting differently
• Week 8-12: Significant body recomposition — reduced waist circumference, improved muscle definition, enhanced recovery between workouts

Monitoring

Fasting insulin and glucose at baseline, 6 weeks, and 12 weeks. IGF-1 levels to confirm GH response. Body composition analysis (DEXA preferred) at baseline and end of cycle. Lipid panel.

"AOD-9604 and CJC-1295 is my go-to body composition stack because it works with the body's physiology rather than overriding it. You're not injecting growth hormone — you're optimizing your own production and directing fat metabolism where it needs to go."

— Dr. Adrian Kovac, Hatter Labs

Stack 4: Immune Support — Thymosin Alpha-1 + LL-37

The Rationale

Thymosin Alpha-1 (Ta1) is an immunomodulatory peptide that enhances T-cell maturation, dendritic cell function, and natural killer cell activity. It's FDA-approved in over 30 countries for hepatitis and used clinically for chronic infections and immune deficiency. LL-37 (Cathelicidin) is a naturally occurring antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and biofilms.

Ta1 strengthens the adaptive immune system's ability to identify and respond to threats. LL-37 provides direct antimicrobial firepower. Together, they build a layered defense — smarter immune surveillance paired with stronger frontline defense.

Dosing Protocol

• Thymosin Alpha-1: 1.5 mg subcutaneously, twice weekly (Monday/Thursday)
• LL-37: 200-400 mcg subcutaneously, 2-3 times weekly
• Cycle: 8-12 weeks on, 4 weeks off. For chronic conditions, longer courses under close monitoring.

Expected Timeline

• Week 1-2: Improved energy and reduced frequency of minor infections
• Week 3-6: Enhanced immune resilience; faster recovery from illness
• Week 8-12: Measurable improvement in immune markers; significant reduction in infection recurrence for chronic-infection patients

Monitoring

CBC with differential at baseline, 4 weeks, and 8 weeks. NK cell activity and lymphocyte subsets for immune-compromised patients. CRP and ESR for inflammatory tracking.

Stack 5: Cognitive Performance — Selank + Semax

The Rationale

Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin. It modulates GABA, serotonin, and dopamine systems, producing anxiolytic effects without sedation. Semax is a synthetic analog of ACTH(4-10) that enhances BDNF (brain-derived neurotrophic factor) expression, supporting neuroplasticity, memory, and focus.

Selank reduces the anxiety and mental noise that impair cognitive performance. Semax enhances the neurochemical environment for learning, focus, and executive function. Together, they create a state of calm, clear, sustained cognitive output.

Dosing Protocol

• Selank: 150-300 mcg intranasally, 1-2 times daily (morning and early afternoon)
• Semax: 200-600 mcg intranasally, once daily in the morning
• Cycle: 4 weeks on, 2 weeks off. Effects are often apparent within days and build over the cycle.

Expected Timeline

• Day 1-3: Subtle but noticeable reduction in background anxiety (Selank); mild increase in mental clarity (Semax)
• Week 1-2: Improved focus, verbal fluency, and working memory. Reduced procrastination.
• Week 3-4: Peak cognitive enhancement. Many patients describe it as "removing a fog they didn't know was there."

Monitoring

Baseline mental health screening (GAD-7, PHQ-9). Cognitive performance self-assessment at baseline, 2 weeks, and 4 weeks. Blood pressure monitoring (Semax can mildly elevate BP in sensitive individuals).

"Selank and Semax is the stack I personally use during high-output research periods. The combination of anxiety reduction and cognitive enhancement is remarkable — and unlike stimulants, there's no crash, no tolerance, and no dependency. It's what your brain would do on its own if it had perfect neurochemistry."

— Dr. Adrian Kovac, Hatter Labs

Cycling Schedules and Safety Principles

Cycling — alternating periods of use and rest — is non-negotiable in peptide stacking. Without cycling, receptor desensitization can blunt efficacy, and the body's feedback mechanisms may be chronically disrupted.

General Cycling Guidelines

• BPC-157 + TB-500: 8-12 weeks on, 4 weeks off. Can restart if injury persists.
• DSIP + Epithalon: Epithalon 20 days on, 4-6 months off. DSIP can be used more flexibly but should have periodic breaks (5 days on / 2 off).
• AOD-9604 + CJC-1295: 12 weeks on, 4 weeks off. Reassess body composition before restarting.
• Ta1 + LL-37: 8-12 weeks on, 4 weeks off. Longer cycles under medical supervision for chronic conditions.
• Selank + Semax: 4 weeks on, 2 weeks off. Shortest cycle due to neurochemical modulation.

Interaction Considerations

Most peptide stacks are well-tolerated because the compounds operate through different receptor systems. However, some caution applies:

• Avoid stacking multiple GH-stimulating peptides (e.g., CJC-1295 + Ipamorelin + MK-677). Pick one GH pathway and support it, don't flood it.
• Monitor insulin sensitivity when using GH-related peptides alongside body composition stacks. GH can reduce insulin sensitivity over time.
• Space intranasal peptides by at least 15 minutes if using both Selank and Semax to ensure adequate nasal absorption of each.
• Don't stack immune-stimulating peptides in patients with active autoimmune conditions — enhanced immune surveillance can worsen autoimmune flares.

When Not to Stack

More is not always better. Dr. Kovac identifies several scenarios where single-peptide protocols are preferable:

• First-time peptide users: Always start with a single peptide to establish individual tolerance and response before adding a second compound.
• Patients on multiple medications: Pharmacological complexity increases with every compound. Keep the peptide protocol simple when the medication list is long.
• Active autoimmune disease: Immune-modulating stacks require extreme caution. Single-peptide trials with close monitoring are safer.
• Pregnancy or nursing: Insufficient safety data for most peptides. Avoid stacking entirely.
• Budget constraints: A well-dosed single peptide outperforms an underdosed stack every time. If cost limits the protocol, choose one compound and use it properly.

"The best peptide stack is the simplest one that achieves the clinical goal. I'd rather see a patient on one peptide at the right dose for the right duration than on four peptides at half doses because it seemed more advanced. Precision beats complexity."

— Dr. Adrian Kovac, Hatter Labs

Building Your First Stack

If you're new to peptide stacking, Dr. Kovac recommends starting with the recovery stack (BPC-157 + TB-500). It has the broadest applicability, the best safety profile, and the most clinical data supporting the combination. Master that pairing, observe the synergy firsthand, and then expand into goal-specific stacks as your experience — and your patients' needs — grow.

The future of peptide therapy is personalized combinations, not one-size-fits-all single compounds. But personalization requires knowledge, monitoring, and a commitment to systematic protocols over guesswork. Build the foundation first. The advanced stacks will follow.